A new drug that prompts cancer cells to self-destruct while sparing healthy cells is now entering phase I clinical trials in humans. The drug, called PAC-1, first showed promise in the treatment of pet dogs with spontaneously occurring cancers, and is still in clinical trials in dogs with osteosarcoma.
With antibiotic resistance on the rise, scientists are looking for innovative ways to combat...
Scientists around the world make use of cell culture techniques on a daily basis. Whether they...
Researchers at the Univ. of North Carolina School of Medicine have found that the blood platelet...
An experimental antiviral drug shows some early, encouraging signs of effectiveness in its first human test against Ebola in West Africa, but only if patients get it when their symptoms first appear. A study of the drug, favipiravir, is still in early stages in West Africa, and too few people have been treated to really know whether the drug helps.
Case Western Reserve Univ. dental researcher Pushpa Pandiyan has discovered a new way to model how infection-fighting T cells cause inflammation in mice. The hope is that the discovery can lead to new therapies or drugs that jump-start weakened or poorly functioning immune systems. Pandiyan believes the process could lead to identifying and testing new drugs to replace antifungal medicines.
Chemical engineers have designed a new type of self-healing hydrogel that could be injected through a syringe. Such gels, which can carry one or two drugs at a time, could be useful for treating cancer, macular degeneration, or heart disease, among other diseases, the researchers say.
Researchers have long sought alternatives to morphine that curb its side effects, including dependency, nausea and dizziness. Now, an experiment at SLAC National Accelerator Laboratory has supplied the most complete atomic-scale map of such a compound docked with a cellular receptor that regulates the body’s pain response and tolerance.
Viruses are masters of outsourcing, entrusting their fundamental function– reproduction– to the host cells they infect. But it turns out this highly economical approach also creates vulnerability. Researchers have found an unexpected way the immune system exploits the flu virus’ dependence on its host’s machinery to create new viruses capable of spreading infection.
For patients with diabetes, insulin is critical to maintaining good health and normal blood-sugar levels. However, it’s not an ideal solution because it can be difficult for patients to determine exactly how much insulin they need to prevent their blood sugar from swinging too high or too low. Massachusetts Institute of Technology engineers hope to improve treatment for diabetes patients with a new type of engineered insulin.
It took 16 years of twists and turns. Over and over, Dr. Nancy Sullivan thought she was close to an Ebola vaccine, only to see the next experiment fail. "A case of resuscitation more than once," is how the National Institutes of Health researcher describes the journey.
For years, treating scratches and burns to the eyes has usually involved dropping medicine onto the eyes several times a day, sometimes for weeks: a treatment that lends itself to missed doses and other side effects. But scientists are now reporting a novel, drug-releasing wafer that patients can put directly on their affected eyes just once a day. The team says the device works better than drops and could help patients recover faster.
Federal health regulators on Tuesday approved a highly anticipated medicine from Pfizer Inc. to treat postmenopausal women with a certain type of advanced breast cancer who have not already taken other drugs. The Food and Drug Administration approved Ibrance for women who have tumors that do not contain a protein known as HER-2. Ibrance, known generically as palbociclib, works by blocking molecules linked to cancer cell growth.
Ten years after the 2005 Paris Declaration on Aid Effectiveness reported on the need for better coordination in the global fight against disease, global pharmaceutical supply chains remain fragmented and lack coordination, facing at least 10 fundamental challenges, according to a newly published paper.
President Barack Obama is calling for an investment to move away from one-size-fits-all-medicine, toward an approach that tailors treatment to your genes. The White House said Friday that Obama will ask Congress for $215 million for what he's calling a precision medicine initiative. The ambitious goal: Scientists will assemble databases of about a million volunteers to study their genetics to learn how to individualize care.
Low doses of metformin, a widely used diabetes medication and a gene inhibitor known as BI2536 can successfully halt the growth of late-stage prostate cancer tumors, a Purdue Univ. study finds. Prostate cancer causes the second-highest number of cancer-related deaths in men in the U.S., and methods of treating advanced prostate cancer are limited.
A new study by Univ. of Kentucky Markey Cancer Center researchers suggests that targeting a key enzyme and its associated metabolic programming may lead to novel drug development to treat lung cancer. Cancer cells undergo metabolic alterations to meet the increased energy demands that support their excess growth and survival.
Lori Simons took the bright orange pill at 3 a.m. Eight hours later, doctors sliced into her brain, looking for signs that the drug was working. She is taking part in one of the most unusual cancer experiments in the nation. With special permission from the Food and Drug Administration and multiple drug companies, an Arizona hospital is testing medicines very early in development and never tried on brain tumors before.
Two new drug compounds appear to be effective in treating endometriosis, a disorder that, like MS, is driven by estrogen and inflammation, scientists report in Science Translational Medicine. The researchers hope to eventually use the new compounds and others like them to treat a variety of disorders linked to estrogen signaling and inflammation.
As predators go, cone snails are slow moving and lack the typical fighting parts. They’ve made up for it by producing a vast array of fast-acting toxins that target the nervous systems of prey. A new study reveals that some cone snails add a weaponized form of insulin to the venom cocktail they use to disable fish.
More efficient medical treatments could be developed thanks to a new method for triggering the rearrangement of chemical particles. The new method, developed at the Univ. of Warwick, uses two “parent” nanoparticles that are designed to interact only when in proximity to each other and trigger the release of drug molecules contained within both.
A regime of anti-HIV drugs has the potential to protect against infection in the first place. But real life can interfere; the effectiveness of this prophylactic approach declines if the medications aren’t taken as prescribed. HIV researchers hope a new compound, known as cabotegravir, could make dosing easier for some because the drug would be administered by injection once every three months.
Chemists have made a significant advancement to directly functionalize C-H bonds in natural products by selectively installing new carbon-carbon bonds into highly complex alkaloids and nitrogen-containing drug molecules. C-H functionalization is a much more streamlined process than traditional organic chemistry, holding the potential to greatly reduce the time and number of steps needed to create derivatives of natural products.
In the midst of a worrisome flu season, health officials are pushing doctors to prescribe antiviral medicines. The Centers for Disease Control and Prevention on Friday sent a new alert to doctors, advising prompt use of Tamiflu and other antivirals for hospitalized flu patients and those at higher risk for complications like pneumonia.
For years, pathogens’ resistance to antibiotics has put them one step ahead of researchers, which is causing a public health crisis, according to Northeastern Univ. Distinguished Prof. Kim Lewis. But in new research, Lewis and his colleagues present a newly discovered antibiotic that eliminates pathogens without encountering any detectable resistance.
A major barrier to finding a cure for HIV/AIDS is the presence of latent HIV in the cells of chronically infected individuals. But a team of Yale and Johns Hopkins researchers may have pinpointed a strategy for eliminating the residual virus. Despite treatment with antiretroviral therapy, HIV persists in patients in a latent reservoir.
Researchers at North Carolina State Univ. and the Univ. of North Carolina at Chapel Hill have uncovered a novel approach to creating inhalable vaccines using nanoparticles that shows promise for targeting lung-specific diseases, such as influenza, pneumonia and tuberculosis.
Federal health experts have unanimously endorsed a Novartis drug which is expected to become the first lower-cost copy of a biotech drug to reach the U.S. market. A panel of FDA experts ruled that the company's version of Neupogen is highly similar to Amgen's original blockbuster biotech drug, which is used to boost blood cells that help cancer patients fight off infections.
An international team of researchers has developed a drug delivery technique that utilizes graphene strips as “flying carpets” to deliver two anticancer drugs sequentially to cancer cells, with each drug targeting the distinct part of the cell where it will be most effective. The technique was found to perform better than either drug in isolation when tested in a mouse model targeting a human lung cancer tumor.
- Page 1